Herbal medicinal products in treatment of respiratory infections


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Current pandemic of the new coronavirus infection COVID-19 has highlighted the leading role of acute respiratory infections (including influenza and ARVI) in the structure of infectious diseases and their impact at socio-economic indicators. Herbal medicinal products play an important role in the symptomatic and pathogenetic treatment of these diseases. They provide a wide range of positive effects in combination with a low risk of adverse events, including comorbid patients and children. Current review presents the substantiation for the use of a Pelargonium sidoides extract-based medicine at the outpatient stage of providing medical care to acute respiratory diseases patients.

Full Text

Restricted Access

About the authors

A. L Vertkin

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: kafedrakf0mail.ru.elibrary.ru
127473, Moscow, 20/1 Delegatskaya Str

M. M Shamuilova

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: kafedrakf0mail.ru
127473, Moscow, 20/1 Delegatskaya Str

G. Yu Knorring

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

127473, Moscow, 20/1 Delegatskaya Str

References

  1. Грипп. ВОЗ, 2018. Доступ: https://www.who.int/ru/news-room/factsheets/detail/influenza-(seasonal) (дата обращения - 01.10.20211. @@Influenza. World Health Organization, 2018. Available at: https://www.who.int/ru/news-room/factsheets/detai1/inf1uenza-(seasona1) (date of access - 01.10.2021) (In Russ.).
  2. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2016 году: государственный доклад. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. М. 2017; 220 с. @@On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2016: state report. Federal Service for Supervision of Consumer Rights Protection and Human Welfare. Moscow. 2017; 220 pp. (In Russ.).
  3. Ющук Н.Д., Хадарцев О.С. Профилактика гриппа и острых респираторных вирусных инфекций с учетом особенности их эпидемического процесса. Инфекционные болезни: новости, мнения, обучение. 2018; 2: 44-51. @@Yushchuk N.D., Khadartsev O.S. Prevention of influenza and acute respiratory viral infections and their epidemic process characteristics. Infektsionnyye botezni: novosti, mneniya, obucheniye = Infectious Diseases: News, Views, Education. 2018; 2: 44-51 (In Russ.). doi: https://dx.doi.org/10.24411/2305-3496-2018-12004.
  4. Колбин А.С., Гомон Ю.М., Балыкина Ю.Е. с соавт. Социально-экономическое и глобальное бремя COVID-19. Качественная клиническая практика. 2021; 1: 24-34. @@Kolbin A.S., Gomon Yu.M., Balykina Yu.E. et at. Socioeconomic and global burden of COVID-19. Kachestvennaya ktinicheskaya praktika = Good Clinical Practice. 2021; 1: 24-34 (In Russ.). doi: https://dx.doi.org/10.37489/2588-0519-2021- 1-24-34.
  5. Patterson K.D., Pyle G.F. The geography and mortality of the 1918 influenza pandemic. Bull Hist Med. 1991; 65(1): 4-21.
  6. Johnson N.P, Mueller J. Updating the accounts: global mortality of the 1918-1920 «Spanish» influenza pandemic. Bull Hist Med. 2002; 76(1): 105-15.
  7. Available at: https://ourworldindata.org/coronavirus (date of access - 01.10.2021).
  8. Watkins K., Sridhar D. Pneumonia: a global cause without champions. Lancet. 2018; 392(10149): 718-19. doi: 10.1016/S0140-6736(18)31666-0.
  9. Верткин А.Л., Прохорович Е.А., Намазова Л.С. с соавт. Оптимизация эмпирической терапии внебольничной пневмонии у больных пожилого и старческого возраста. РМЖ. 2002; 16: 708-712. @@Vertkin A.L., Prokhorovich E.A., Namazova L.S. et al. Optimization of empiric therapy for community-acquired pneumonia in elderly and senile patients. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2002; 16: 708-712 (In Russ.).
  10. Anheyer D., Cramer H., Lauche R. et al. Herbal medicine in children with respiratory tract infection: Systematic review and meta-analysis. Acad Pediatr. 2018; 18(1): 8-19. doi: 10.1016/j.acap.2017.06.006.
  11. Клячкина И.Л., Рыбаченко В.В., Кнорринг ГЮ., Воронина Е.В. Опыт и перспективы системной энзимотерапии при лечении заболеваний дыхательных путей. Доктор.Ру. 2006; 2: 31-35. @@Klyachkina I.L., Rybachenko V.V., Knorring G.Yu., Voronina E.V. Experience and prospects of systemic enzyme therapy in the treatment of respiratory diseases. DoctorRu. 2006; 2: 31-35 (In Russ.).
  12. Chalumeneau M., Salannave B., Assathiany R. et al. [Connaisance et application par des pediatres deville de la conference de concensus sur les rhinopharyngites aigues de l'enfant]. Arch. Pediatr. 2000; 7(5): 481-88.
  13. Bladt S., Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo. Phytomedicine. 2007; 14(6): 2-4. doi: 10.1016/j. phymed.2006.11.030.
  14. Холодова И.Н., Холодов Д.И. Как снизить резистентность к антибактериальной терапии? Медицинский совет. 2017; 19: 84-89. [Kholodova I.N., Kholodov D.I. How to reduce resistance to antibacterial therapy? Meditsinskiy sovet = Medical Council. 2017; 19: 84-89 (In Russ.)]. doi: https://doi.org/10.21518/2079-701X-2017-19-84-89.
  15. Kolodziej H., Kiderlen A.F In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and related herbal drug рreparation EPs 7630. Phytomedicine. 2007, 14(6): 18-26. doi: 10.1016/j.phymed.2006.11.020.
  16. Григорян С.С., Гаращенко Т.И., Исаева Е.К. с соавт. Противовирусное действие препарата Умкалор на продукцию вируса in vitro. Детская оториноларингология. 2014; 2: 1-4. @@Grigoryan S.S., Garashchenko T.I., Isaeva E.K. et al. Antiviral effect of the drug Umckalor on the production of the virus in vitro. Detskaya otorinolaringologiya = Pediatric Otorhinolaryngology. 2014; 2: 1-4 (In Russ.).
  17. Roth M., Fang L., Stolz, D., Tamm M. Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. 2019; 14(2): e0210702. doi: 10.1371/journal.pone.0210702.
  18. Keck T., Strobl A., Weinhaeusel A. et al. Pelargonium extract EPs 7630 in the treatment of human coronavirus-associated acute respiratory tract infections - a secondary subgroup-analysis of an open-label, uncontrolled clinical trial. Front Pharmacol. 2021; 12: 666546. doi: 10.3389/ fphar.2021.666546.
  19. Bereznoy V., Riley D., Wassmer G., Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-hemolytic Streptococcus tonsillopharyngitis: A randomized, double-blind, placebo-controlled trial. Altern Ther Health Med. 2003; 9(5): 68-79.
  20. Conrad A., Jung I., Tioua D. et al. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro. Phytomedicine. 2007;14(6): 52-59. doi: 10.1016/j.phymed.2006.11.018.
  21. Janecki A., Conrad A., Engels I. et al. Evaluation of an aqueous-ethanolic extract from Pelargonium sidoides (EPs 7630) for its activity against group A-streptococci adhesion to human HEp-2 epithelial cells. J Ethnopharmacol. 2011; 133(1): 147-52. doi: 10.1016/j.jep.2010.09.018.
  22. Matthys H., Heger M. Treatment of acute bronchitis with liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): A randomized, double-blind, placebo-controlled multicentre study. Curr Res Opin. 2007; 23(2): 323-31. doi: 10.1185/030079906X167318.
  23. Елкина Т.Н., Грибанова О.А. Монотерапия острых респираторных инфекций препаратом «Умкалор». РМЖ. 2008; 16: 1968-1971. @@Elkina T.N., Gribanova O.A. Monotherapy of acute respiratory infections with the drug Umckalor Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2008, 16: 1968-1971 (In Russ.).
  24. Park S.M., Min B.G., Jung J.Y. et al. Combination of Pelargonium sidoides and Coptis chinensis root inhibits nuclear factor kappa B-mediated inflammatory response in vitro and in vivo. BMC Complement Altern Med. 2018; 18(1): 20. doi: 10.1186/s12906-018-2088-x.
  25. Peric A., Vezmar Kovacevic S., Barac A. et al. Effects of Pelargonium sidoides extract on chemokine levels in nasal secretions of patients with non-purulent acute rhinosinusitis. J Drug Assess. 2020; 9(1): 145-50. doi: 10.1080/21556660.2020.1838176.
  26. Haidvogl M., Heger M. Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: report of a multicentre observational study. Phytomedicine. 2007; 14(Suppl 6): 60-64. doi: 10.1016/j.phymed.2006.11.014.
  27. Kolodziej H. Antimicrobial, antiviral and immunomodulatory activity studies of Pelargonium sidoides (EPs 7630) in the context of health promotion. Pharmaceuticals. 2011; 4(10): 1295-314. doi: 10.3390/ph4101295.
  28. Witte K., Koch E., Volk H.-D. et al. The Pelargonium Sidoides extract EPs 7630 drives the innate immune defense by activating selected map kinase pathways in human monocytes. PLoS One. 2015; 10 (9): e0138075. doi: 10.1371/journal.pone.0138075.
  29. Luna L.A. Jr, Bachi A.L.L., Novaes e Brito R.R. et al. Immune responses induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise: Modulation of secretory IgA, IL-6 and IL-15. Phytomedicine. 2011; 18 (4): 303-08. doi: 10.1016/j. phymed.2010.08.003.
  30. Matthys H., Kamin W., Funk P, Heger M. Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children. Phytomedicine. 2007; 14(Suppl 6): 69-73. doi: 10.1016/j.phymed.2006.11.015.
  31. Dome L., Schuster R. [Umckaloabo - a phytotherapeutic alternative for acute bronchitis in childhood?] Arztez Naturheilverf. 1996; 37: 216-22.
  32. Haidvogl M., Schuster R., Heger M. [Acute bronchitis in children - multicenter study on the effectiveness and tolerability of the phytoterapeutic Umckaloabo]. Z Phytoterapie. 1996; 17: 300-13.
  33. Konig I. [Respiratory tract therapy on a natural basis]. Therapie Woche. 1995; 45: 1123-26.
  34. Крюков А.И., Кунельская Н.Л., Ивойлов А.Ю. с соавт. Клиническая эффективность Pelargonium sidoides - EPs 7630 в комплексной терапии детей с хроническим аденоидитом, перенесших аденотомию. Медицинский совет. 2017; 16: 28-32. @@Kryukov A.I., Kunelskaya N.L., Ivoilov A.Yu. et al. Clinical efficacy of pelargonium sidoides EPS® 7630 in complex therapy of children with chronic adenoiditis, who has undergone adenoidectomy. Meditsinskiy sovet = Medical Council. 2017; 16: 28-32 (In Russ.). doi: https://doi.org/10.21518/2079-701X-2017-16-28-32.
  35. Bereznoy V.V., Riley D.S., Wassmer G., Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group Abeta-hemolytis Streptococcus tonsillopharygits; a randomized, double-blind, placebo-controlled trial. Altern Ther Health Med. 2003; 9(5): 68-79.
  36. Chuchalin A.G., Berman E., Lehmacher W. Treatment of acute bronchitis in adults with a Pelargonium sidoides preparation (EPs7630); A randomized, double-blind, placebo-controlled trial. Explore (NY). 2005; 1(6): 437-45. doi: 10.1016/j.explore.2005.08.009.
  37. Чучалин А.Г, Берман Б., Лемахер В. Лечение острого бронхита у взрослых экстрактом пеларгонии сидовидной (Pelargonium sidoides; EPs 7630): рандомизированное двойное слепое плацебо-контролируемое исследование. Пульмонология. 2007; 6: 49-55. @@Chuchalin A.G., Berman В., Lemakher V. Treatment of acute bronchitis in adults with extract of pelargonium sidoides: a randomised, double-blind, placebo controlled trial. Pul'monologiya = Pulmonology. 2007; 6: 49-55 (In Russ.).
  38. Agbabiaka T.B., Guo R., Ernst E. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. Phytomedicine. 2008; 15(5): 378-85. doi: 10.1016/j.phymed.2007.11.023. Epub 2008 Jan 28. Erratum in: Phytomedicine. 2009; 16(8): 798-99.
  39. Matthys H., Heger M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): A randomized, double-blind, placebo-controlled, multicentre study. Curr Med Res Opin. 2007; 23(2): 323-31. doi: 10.1185/030079906X167318.
  40. Bachert C., Schapowal A., Funk P, Kieser M. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: A randomized, double-blind, placebo-controlled trial. Rhinology. 2009; 47(1): 51-58.
  41. Timmer A., Gunther J., Motschall E. et al. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev. 2013; 10: CD006323. doi: 10.1002/14651858.CD006323.pub3.
  42. Anheyer D., Cramer H., Lauche R. et al. Herbal medicine in children with respiratory tract infection: Systematic review and meta-analysis. Acad Pediatr 2018; 18(1): 8-19. doi: 10.1016/j.acap.2017.06.006.
  43. Careddu D., Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med. 2018; 11: 91-98. doi: 10.2147/IJGM.S154198.
  44. Seifert G., Brandes-Schramm J., Zimmermann A. et al. Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections. BMC Pediatr 2019; 19(1): 119. doi: 10.1186/s12887-019-1473-z.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies